samedan logo
 
 
 
spacer
home > ebr > summer 2021 > bio-europe® 2021 digital
PUBLICATIONS
European Biopharmaceutical Review

BIO-Europe® 2021 Digital

EBR: What lessons did you learn from BIO-Europe Digital 2020, and how have those findings reflected upon the decisions taken in relation to BIO-Europe 2021?

Pam Putz: BIO-Europe Digital 2020 was a remarkable success and proved that digital partnering is an effective tool during this crisis to keep the deal flow going. As we started to plan for this year’s edition, we factored in feedback from all our international stakeholders: small biotechs that look for a high ROI on their partnering meetings, pharma companies and other large players with yet to be lifted travel restrictions, our host, and other economic development groups we partner with.

Thankfully, we also have strong data points to guide our decision: we know that two-thirds of all meetings that take place at BIO-Europe involve at least one attendee from North America, Asia, or Australia. Our mission with BIO-Europe has always focused on connecting the international life science community, and the unique value we provide is to meet the world at BIO-Europe in three days. Factoring in what we have learned over the last 18 months, we have come to the decision that we can best meet the needs of the global life science community in a virtual setting.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Pam Putz is Managing Director at EBD Group.

Our mission with BIO-Europe has always focused on connecting the international life science community, and the unique value we provide is to meet the world at BIO-Europe during a three day event and we’ll do it again later this year, over four days, 25-28 October, 2021.
spacer
Pam Putz
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Tempus Announces Agreement With Janssen R&D to Leverage AI/ML and Real-World Evidence to Enhance the Discovery and Development of Oncology Therapies

Tempus, a leader in artificial intelligence and precision medicine, today announced the expansion of its multi-year agreement with Janssen Research & Development, LLC (Janssen).
More info >>

White Papers

Interface: Drug Delivery Devices

Phillips-Medisize

A family is packing for its annual summer trek to the cottage by the lake. Along with fishing gear, sunscreen, and life vests, the checklist also includes another kind of life saver – an autoinjector that delivers two doses of epinephrine to treat anaphylaxis, a severe and potentially lifethreatening allergic reaction.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement